We are honored to highlight the recently started COLLISION trial that will compare thermal ablation to surgical resection for small resectable colorectal liver metastases (CRLM 0-3 cm) [1] . Since colorectal cancer is the third most common malignancy worldwide and the second most common cause of cancer-related deaths in developed countries, this trial encompasses a major medical concern [2] . Although approximately half of all patients develop liver metastases in course of their disease, only 15-20% is considered eligible for curative intent surgical resection. For patients with an impaired general health status, history of extensive abdominal surgery, the presence of lesions with an unfavorable anatomical location or an insufficient future liver remnant to perform partial hepatectomy, thermal ablation nowadays is accepted worldwide to eliminate small unresectable CRLM. The minimal invasive and parenchyma-sparing nature, good and still improving efficacy with the potential to repeat procedures in case of local tumor progression, low costs and short hospital stay of thermal ablation have made it impossible to postulate generally accepted resectability criteria, especially for small and deep-seeded CRLM that require major hepatectomy [3] .
Patients with at least 1 resectable and ablatable CRLM (B 3 cm), up to ten lesions, a good performance status, no extrahepatic disease and no prior liver treatment are considered eligible (Fig. 1) . Supplementary resection(s) for resectable tumors [ 3 cm and ablation(s) for unresectable tumors B 3 cm are allowed. The primary endpoint is overall survival. Secondary endpoints are disease-free survival, time-to-(local)-progression, primary and assisted technique efficacy, mortality, length of hospital stay, assessment of quality of life and cost-effectiveness.
If thermal ablation proves to be non-inferior (i.e., equal or superior), a switch in treatment method will lead to a reduction in morbidity and mortality, length of hospital stay and incremental costs without compromising oncological outcome for patients with small resectable CRLM. The first study results are expected at the end of 2025.
